FDA Accepts IND of NK Cell Therapy for HER2 Positive Solid Tumors

Jan 09, 2020

|

NEW YORK – Biotech company Acepodia said Thursday that the US Food and Drug Administration accepted the investigational new drug application for its new antibody-cell conjugate based immunotherapy, ACE1702, for patients with HER2-expressing solid tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Accepts IND of NK Cell Therapy for HER2 Positive Solid Tumors

To read the full story....

Breaking News

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Featured White Papers

What's Popular?

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

Phase I Study of Novel Drug Shows Preliminary Activity in Mesothelin-Expressing Tumors

Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications

Sponsorships